Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 MeetingBusiness Wire • 10/01/20
Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon DiseaseBusiness Wire • 09/02/20
Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant OsteopetrosisBusiness Wire • 08/27/20
Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of ExcellenceBusiness Wire • 08/26/20
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent ProgressBusiness Wire • 08/05/20
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase DeficiencyBusiness Wire • 07/13/20
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant OsteopetrosisBusiness Wire • 06/29/20
Rocket Pharmaceuticals: Updating Our Bullish View For Recent Events - Still A BUYSeeking Alpha • 05/27/20
Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to BuyZacks Investment Research • 01/06/20
Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue?Zacks Investment Research • 12/04/19